Back

Reduced sera neutralization to Omicron SARS-CoV-2 by bothinactivated and protein subunit vaccines and the convalescents

Zhao, X.; Li, D.; Ruan, W.; Zhang, R.; Zheng, A.; Qiao, S.; Zheng, X.; Zhao, Y.; Chen, Z.; Dai, L.; Han, P.; Gao, G. F.

2021-12-20 immunology
10.1101/2021.12.16.472391 bioRxiv
Show abstract

Omicron variant continues to spread all over the world. There are lots of scientific questions remaining to be answered for such a devastating variant. There are a dozen of vaccines already in clinical use. The very urgent scientific question would be whether or not these vaccines can protect Omicron variant. Here, we tested the sera from both convalescents and vaccine recipients receiving either inactivated or protein subunits vaccines (CoronaVac from Sinovac, or BBIBP-CoV from Sinopharm, or ZF2001 from Zhifei longcom) for the binding antibody titers (ELISA) and neutralization antibodies titers (pseudovirus neutralization assay). We showed that Omicron do have severe immune escape in convalescents, with 15 of 16 were negative in neutralization. By contrast, in vaccinees who received three jabs of inactivated or protein subunit vaccine, the neutralizing activity was much better preserved. Especially in the ZF2001 group with an extended period of the second and third jab (4-6 months) remains 100% positive in Omicron neutralization, with only 3.1-folds reduction in neutralizing antibody (NAb) titer. In this case, we proposed that, the multi-boost strategy with an extended interval between the second and third jab for immune maturation would be beneficial for NAb against devastating variants such as Omicron.

Matching journals

The top 5 journals account for 50% of the predicted probability mass.

1
Cell Discovery
57 papers in training set
Top 0.1%
34.0%
2
Signal Transduction and Targeted Therapy
30 papers in training set
Top 0.1%
7.8%
3
Emerging Microbes & Infections
74 papers in training set
Top 0.2%
4.3%
4
eLife
5828 papers in training set
Top 31%
3.5%
5
Frontiers in Immunology
638 papers in training set
Top 4%
3.2%
50% of probability mass above
6
Science Bulletin
21 papers in training set
Top 0.1%
3.2%
7
Med
39 papers in training set
Top 0.1%
3.2%
8
Human Vaccines & Immunotherapeutics
25 papers in training set
Top 0.2%
2.4%
9
Cell Research
51 papers in training set
Top 0.3%
2.4%
10
Vaccine
203 papers in training set
Top 1%
2.4%
11
The Lancet Infectious Diseases
73 papers in training set
Top 0.6%
2.1%
12
Cellular & Molecular Immunology
14 papers in training set
Top 0.1%
2.1%
13
Clinical and Translational Medicine
31 papers in training set
Top 0.2%
2.1%
14
Vaccines
198 papers in training set
Top 2%
2.0%
15
iScience
1154 papers in training set
Top 15%
1.9%
16
Scientific Reports
3612 papers in training set
Top 55%
1.7%
17
Molecular Therapy
81 papers in training set
Top 1.0%
1.7%
18
Protein & Cell
25 papers in training set
Top 0.3%
1.5%
19
eBioMedicine
183 papers in training set
Top 3%
1.4%
20
Nature Communications
5641 papers in training set
Top 49%
1.3%
21
The Lancet Regional Health - Western Pacific
15 papers in training set
Top 0.1%
1.3%
22
The Innovation
13 papers in training set
Top 0.2%
1.1%
23
Microbiology Spectrum
469 papers in training set
Top 10%
0.8%
24
Journal of Medical Virology
140 papers in training set
Top 3%
0.8%
25
National Science Review
21 papers in training set
Top 0.3%
0.8%